![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0019.png)
Volume 6, Issue 4 (Suppl)
Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 73
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6
th
International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4
th
EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Evaluation of medicine distribution, regulatory privatisation, social welfare services and its alternatives
Abdeen Omer
Occupational Health Administration, Ministry of Health, Sudan
T
he strategy of price liberalisation and privatisation had been implemented in Sudan over the last decade, and has had a
positive result on government deficit. The investment law approved recently has good statements and rules on the above
strategy in particular to pharmacy regulations. Under the pressure of the new privatisation policy, the government introduced
radical changes in the pharmacy regulations. To improve the effectiveness of the public pharmacy, resources should be switched
towards areas of need, reducing inequalities and promoting better health conditions. Medicines are financed either through
cost sharing or full private and the role of the private services is significant. A review of reform of financing medicines in Sudan
is given in this article. Also, it highlights the current drug supply system in the public sector, which is currently responsibility of
the Central Medical Supplies Public Corporation (CMS). In Sudan, the researchers did not identify any rigorous evaluations or
quantitative studies about the impact of drug regulations on the quality of medicines and how to protect public health against
counterfeit or low-quality medicines, although it is practically possible. However, the regulations must be continually evaluated
to ensure the public health is protected against by marketing high quality medicines rather than commercial interests, and the
drug companies are held accountable for their conducts.
abdeenomer2@yahoo.co.ukClin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-026